ChromaDex Corporation (NASDAQ:CDXC) is reporting third quarter financial results on Wednesday 4th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, CDXC is expected to report 3Q20 loss of $ 0.1 per share from revenue of $ 14.29 million.
For the full year, analysts anticipate top line of $ 60.10 million, while looking forward to loss of $ 0.36 per share bottom line.
Previous Quarter Performance
ChromaDex Corporation outlined loss for the second quarter of $ 0.06 per share, from the revenue of $ 15.29 million. The quarterly revenues up 37.75 percent compared with the same quarter last year. Wall street analysts are predicting, CDXC to report 2Q20 loss of $ 0.10 per share from revenue of $ 13.87 million. The bottom line results beat street analysts by $ 0.04 or 40.00 percent, at the same time, top line results outshined analysts by $ 1.42 million or 10.24 percent.
Stock Performance
Shares of ChromaDex Corporation traded up $ 0.27 or 6.08 percent on Tuesday, reaching $ 4.71 with volume of 193.20 thousand shares. ChromaDex Corporation has traded high as $ 4.72 and has cracked $ 4.45 on the downward trend
According to the previous trading day, closing price of $ 4.71, representing a 77.60 % increase from the 52 week low of $ 2.50 and a 26 % decrease over the 52 week high of $ 6.00.
The company has a market capital of $ 290.25 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
ChromaDex Corporation will be hosting a conference call at 4:30 PM eastern time on 4th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.chromadex.com
ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function. It also provides reference standards and fine chemicals to conduct quality control of raw materials and finished products in dietary supplements, cosmetics, food and beverages, and pharmaceutical industries.
